Literature DB >> 25730237

Association of chronic pelvic pain and endometriosis with signs of sensitization and myofascial pain.

Pamela Stratton1, Izabella Khachikyan, Ninet Sinaii, Robin Ortiz, Jay Shah.   

Abstract

OBJECTIVE: To evaluate sensitization, myofascial trigger points, and quality of life in women with chronic pelvic pain with and without endometriosis.
METHODS: A cross-sectional prospective study of women aged 18-50 years with pain suggestive of endometriosis and healthy, pain-free volunteers without a history of endometriosis. Patients underwent a physiatric neuromusculoskeletal assessment of clinical signs of sensitization and myofascial trigger points in the abdominopelvic region. Pain symptoms, psychosocial, and quality-of-life measures were also assessed. All participants with pain underwent laparoscopic excision of suspicious lesions to confirm endometriosis diagnosis by histologic evaluation.
RESULTS: Patients included 18 with current, biopsy-proven endometriosis, 11 with pain only, and 20 healthy volunteers. The prevalence of sensitization as measured by regional allodynia and hyperalgesia was similar in both pain groups (83 and 82%) but much lower among healthy volunteers (15%, P<.001). Nearly all women with pain had myofascial trigger points (94 and 91%). Adjusting for study group, those with high anxiety (odds ratio [OR] 1.05, 95% confidence interval [CI] 1.004-1.099, P=.031) and depression (OR 1.06, 95% CI 1.005-1.113, P=.032) scores were more likely to have sensitization. Pain patients with any history of endometriosis had the highest proportion of sensitization compared with the others (87% compared with 67% compared with 15%; P<.001). Adjusting for any history of endometriosis, those with myofascial trigger points were most likely sensitized (OR 9.41, 95% CI 1.77-50.08, P=.009).
CONCLUSION: Sensitization and myofascial trigger points were common in women with pain regardless of whether they had endometriosis at surgery. Those with any history of endometriosis were most likely to have sensitization. Traditional methods of classifying endometriosis-associated pain based on disease, duration, and anatomy are inadequate and should be replaced by a mechanism-based evaluation, as our study illustrates. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00073801. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Year:  2015        PMID: 25730237      PMCID: PMC4347996          DOI: 10.1097/AOG.0000000000000663

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  19 in total

Review 1.  Relating Chronic Pelvic Pain and Endometriosis to Signs of Sensitization and Myofascial Pain and Dysfunction.

Authors:  Jacqueline V Aredo; Katrina J Heyrana; Barbara I Karp; Jay P Shah; Pamela Stratton
Journal:  Semin Reprod Med       Date:  2017-01-03       Impact factor: 1.303

2.  Symptoms-Based Phenotypes Among Women With Dysmenorrhea: A Latent Class Analysis.

Authors:  Chen X Chen; Susan Ofner; Giorgos Bakoyannis; Kristine L Kwekkeboom; Janet S Carpenter
Journal:  West J Nurs Res       Date:  2017-09-15       Impact factor: 1.967

3.  Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a pain-focused treatment.

Authors:  Hannah K Tandon; Pamela Stratton; Ninet Sinaii; Jay Shah; Barbara I Karp
Journal:  Reg Anesth Pain Med       Date:  2019-07-08       Impact factor: 6.288

Review 4.  Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders.

Authors:  Barbara Illowsky Karp; Hannah Tandon; Deionna Vigil; Pamela Stratton
Journal:  Int Urogynecol J       Date:  2019-01-07       Impact factor: 2.894

Review 5.  Physical, Complementary, and Alternative Medicine in the Treatment of Pelvic Floor Disorders.

Authors:  Alex Arnouk; Elise De; Alexandra Rehfuss; Carin Cappadocia; Samantha Dickson; Fei Lian
Journal:  Curr Urol Rep       Date:  2017-06       Impact factor: 3.092

6.  Molecular and preclinical basis to inhibit PGE2 receptors EP2 and EP4 as a novel nonsteroidal therapy for endometriosis.

Authors:  Joe A Arosh; JeHoon Lee; Dakshnapriya Balasubbramanian; Jone A Stanley; Charles R Long; Mary W Meagher; Kevin G Osteen; Kaylon L Bruner-Tran; Robert C Burghardt; Anna Starzinski-Powitz; Sakhila K Banu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-21       Impact factor: 11.205

7.  Research Priorities for Endometriosis.

Authors:  Peter A W Rogers; G David Adamson; Moamar Al-Jefout; Christian M Becker; Thomas M D'Hooghe; Gerard A J Dunselman; Asgerally Fazleabas; Linda C Giudice; Andrew W Horne; M Louise Hull; Lone Hummelshoj; Stacey A Missmer; Grant W Montgomery; Pamela Stratton; Robert N Taylor; Luk Rombauts; Philippa T Saunders; Katy Vincent; Krina T Zondervan
Journal:  Reprod Sci       Date:  2016-09-27       Impact factor: 3.060

Review 8.  Re-Examining Myofascial Pain Syndrome: Toward Biomarker Development and Mechanism-Based Diagnostic Criteria.

Authors:  Felipe C K Duarte; Daniel W D West; Lukas D Linde; Samah Hassan; Dinesh A Kumbhare
Journal:  Curr Rheumatol Rep       Date:  2021-07-08       Impact factor: 4.592

Review 9.  [Management of endometriosis pain : Stage-based treatment strategies and clinical experience].

Authors:  Sylvia Mechsner
Journal:  Schmerz       Date:  2021-03-11       Impact factor: 1.107

10.  Widespread myofascial dysfunction and sensitisation in women with endometriosis-associated chronic pelvic pain: A cross-sectional study.

Authors:  Vy T Phan; Pamela Stratton; Hannah K Tandon; Ninet Sinaii; Jacqueline V Aredo; Barbara I Karp; Melissa A Merideth; Jay P Shah
Journal:  Eur J Pain       Date:  2021-01-08       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.